ClinicalTrials.gg
CompletedNCT00496730Updated May 16, 2024Results posted

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)

A Phase 3 interventional study of simvastatin (+) ezetimibe and Comparator: atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
32nd of 97
256 · median 148
Started
2007
with 15 others
Phase 3
50 of 98
1 open now
Registered
27th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 32nd largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 27th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea. Therefore this trial will help evaluate the lipid lowering effect of Vytorin® in asian population with metabolic syndrome.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Metabolic Disorder
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of the metabolic syndrome according to 2005 American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) scientific statement
  • No history of diabetes and 100 \<=LDL-C \<=250 mg/dl

Exclusion criteria

Exclusion Criteria:

  • Myocardial Infarction, coronary artery bypass surgery, or angioplasty within 3 months
  • Congestive heart failure defined by (NYHA) class III or IV
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins
  • Uncontrolled hypertension
  • Unstable angina
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    Vytorin®

    simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks

    Drug: simvastatin (+) ezetimibe

  • Active comparator
    atorvastatin

    atorvastatin 10 mg; tablet, once daily, 8 Weeks

    Drug: Comparator: atorvastatin

Interventions

  • Drugsimvastatin (+) ezetimibe

    Drug pages: Ezetimibe · Simvastatin

    simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks

    Also known as: MK0653A, Vytorin®

  • atorvastatin 10 mg; tablet, once daily, 8 Weeks

    Also known as: Lipitor®

06

What researchers measure

Primary outcomes

  1. Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.

    Time frame: Baseline and 8 Weeks

Secondary outcomes

  1. Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.

    Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment. LDL-C goal is based on National Cholesterol Education Program (NCEP) III guideline (LDL-C goals and cutpoints for therapeutic life changes and drug Therapy in different risk).

    Time frame: Baseline and 8 weeks

Other outcomes

  1. Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Nov 17, 2009

Participant flow

Patients were recruited between June 2007 and May 2008.

Participant flow — Overall Study
MilestoneVytorinAtorvastatin
Started130126
Completed124121
Not completed65
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject22

Outcome measures

PrimaryMean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.
Time frame:
Baseline and 8 Weeks
Reported as:
Mean · Percent of Baseline Value
Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.
Percent of Baseline ValueVytorinAtorvastatin
Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.-49.29 ± 15.22-38.05 ± 12.28
Statistical analysis
  • Vytorin vs Atorvastatin · ANCOVA · p = <0.0001
SecondaryNumber of Patients Attaining LDL-C Goal After 8 Weeks Treatment.

Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment. LDL-C goal is based on National Cholesterol Education Program (NCEP) III guideline (LDL-C goals and cutpoints for therapeutic life changes and drug Therapy in different risk).

Time frame:
Baseline and 8 weeks
Reported as:
Number · Participants attaining LDL-C goal
Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.
Participants attaining LDL-C goalVytorinAtorvastatin
Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.10593
Statistical analysis
  • Vytorin vs Atorvastatin · ANCOVA · p = <0.0001
Other pre-specifiedChange in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.
Time frame:
Baseline and Week 8
Reported as:
Mean · mg/dL
Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.
mg/dLVytorinAtorvastatin
Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.83.52 ± 33.8498.27 ± 21.82
Statistical analysis
  • Vytorin vs Atorvastatin · ANCOVA · p = <0.0001

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vytorin———
Atorvastatin———
Most frequent serious events
Most frequent serious events
EventVytorinAtorvastatin
Hepatic enzyme increasedInvestigations0/1241/121
PyrexiaGeneral disorders0/1241/121
DeathGeneral disorders1/1240/121
Most frequent other events
Showing 10 of 41
Most frequent other events
EventVytorinAtorvastatin
HypercholesterolaemiaMetabolism and nutrition disorders6/1246/121
High Density lipoprotein decreasedInvestigations2/1245/121
HypertriglyceridaemiaMetabolism and nutrition disorders4/1243/121
Hepatic enzyme increasedInvestigations2/1243/121
Abdominal pain upperGastrointestinal disorders2/1243/121
HeadacheNervous system disorders2/1243/121
DizzinessNervous system disorders0/1243/121
Upper respiratory tract infectionInfections and infestations1/1243/121
DiarrhoeaGastrointestinal disorders0/1242/121
Blood Insulin IncreasedInvestigations2/1240/121

Baseline characteristics

Age, Continuous
Age, Continuous(years)VytorinAtorvastatinTotal
Mean58.96 ± 9.4260.26 ± 9.4459.61 ± 9.44
Sex: Female, Male
Sex: Female, Male(Participants)VytorinAtorvastatinTotal
Female364379
Male9483177
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)VytorinAtorvastatinTotal
Mean26.75 ± 3.5926.45 ± 3.3426.61 ± 3.46
Diastolic Blood Pressure
Diastolic Blood Pressure(mm Hg)VytorinAtorvastatinTotal
Mean81.01 ± 8.4782.11 ± 8.4981.55 ± 8.48
LDL-C (low-Density-Lipoprotein-Cholesterol)
LDL-C (low-Density-Lipoprotein-Cholesterol)(mg/dL)VytorinAtorvastatinTotal
Mean159.95 ± 30.33159.95 ± 27.34159.95 ± 28.84
Systolic Blood Pressure
Systolic Blood Pressure(mm Hg)VytorinAtorvastatinTotal
Mean130.81 ± 13.91129.85 ± 14.51130.34 ± 14.19
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2007
First posted
Jul 4, 2007
Start
Jul 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Nov 17, 2009
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00496730
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jul 4, 2007
Start date
Jul 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Nov 17, 2009
Last update
May 16, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin

Start the discussion